Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Public ClinicalTrials.gov record NCT06050122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Study identification
- NCT ID
- NCT06050122
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2024 (Actual)
- Primary completion
- Aug 20, 2026 (Actual)
- Completion
- Sep 14, 2026 (Actual)
- Last update posted
- Sep 18, 2026
2024 – 2026
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwest Arkansas Clinical Trials Center | Rogers | Arkansas | 72758 | — |
| Center for Dermatology Clinical Research | Fremont | California | 94538 | — |
| University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location | Los Angeles | California | 90024 | — |
| The Dermatology Center of Newport | Newport Beach | California | 92660 | — |
| Stanford University - Lucille Packard's Children's Hospital | Redwood City | California | 94063 | — |
| Yale University | New Haven | Connecticut | 06519 | — |
| Dermatology Associates of Tallahassee | Tallahassee | Florida | 32308 | — |
| University of South Florida Health | Tampa | Florida | 33612 | — |
| The University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | 21287-0006 | — |
| University of Michigan Health - Michigan Medicine - University Hospital | Ann Arbor | Michigan | 48109 | — |
| Minnesota Clinical Study Center | New Brighton | Minnesota | 55112 | — |
| MediSearch Clinical Trials | Saint Joseph | Missouri | 64506 | — |
| Schweiger Dermatology P.C. | Verona | New Jersey | 07044 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Health System | Durham | North Carolina | 27710 | — |
| Apex Clinical Research Center | Canton | Ohio | 44718 | — |
| Cleveland Clinic - Main Campus | Cleveland | Ohio | 44195 | — |
| Apex Clinical Research Center | Mayfield Heights | Ohio | 44124 | — |
| SSM Health Dermatology | Oklahoma City | Oklahoma | 73102 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| North Texas Center for Clinical Research | Frisco | Texas | 75034 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06050122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06050122 live on ClinicalTrials.gov.